Vitenskap BIOGEN IDEC AND ABBVIE ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY INVESTIGATING DACLIZUMAB HIGH-YIELD PROCESS IN MULTIPLE SCLEROSIS 17 juni 201415 desember 2019y6.no
